EMA Says Yes To PRIME Designations For Wet AMD & HAE Gene Therapies
Two gene therapies, from Molecular Therapeutics and Intellia Therapeutics respectively, are among the four new products the European Medicines Agency accepted onto it priority medicines scheme this month.
